@article {692070,
	title = {Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer},
	journal = {Arch Pathol Lab Med},
	year = {2022},
	month = {2022 Jun 30},
	abstract = {CONTEXT.{\textemdash}: Multiple procedural techniques can be used to obtain tissue to create a formalin-fixed, paraffin-embedded specimen for comprehensive genomic profiling (CGP) in lung cancer. The literature is mixed on whether the procedure affects CGP success.

OBJECTIVE.{\textemdash}: To examine whether biopsy procedure affects lung cancer CGP success.

DESIGN.{\textemdash}: This was a cross-sectional study of all patients with lung cancer whose specimens were submitted for CGP between January and February 2020. Multiple quality control metrics were used to determine whether cases were successfully profiled.

RESULTS.{\textemdash}: In all, 3312 samples were identified. Overall, 67.5\% (2236 of 3312) were obtained from biopsies, 13.0\% (432 of 3312) from fine-needle aspirations (FNAs), 9.7\% (321 of 3312) from resections, 5.3\% (174 of 3312) from fluid cytology cell blocks, and 4.5\% (149 of 3312) from bone biopsies. Overall, 70.1\% (2321 of 3312) of cases passed CGP, 15.4\% (510 of 3312) of cases were released as qualified reports, and 14.5\% (481 of 3312) of cases failed CGP. Resection samples were the most likely to be successfully sequenced, failing in only 2.8\% (9 of 321) of instances, while fluid cytology specimens were the least likely, failing in 23.0\% (40 of 174) of instances. Biopsy (14.5\% [324 of 2236]), FNA (18.5\% [80 of 432]), and bone biopsy (18.8\% [28 of 149]) specimens failed at intermediate frequencies. On multivariate logistic regression analysis of CGP success on specimen type, fluid cytology (OR, 0.08; 95\% CI, 0.03-0.19), biopsy (OR, 0.25; 95\% CI, 0.11-0.52), FNA (OR, 0.14; 95\% CI, 0.06-0.32), and bone biopsy (OR, 0.07; 95\% CI, 0.03-0.17) specimens had decreased odds of CGP success relative to resection samples. Among patients with successfully sequenced samples, 48.0\% were eligible for at least 1 therapy, based on a companion diagnostic or National Comprehensive Cancer Network biomarker.

CONCLUSIONS.{\textemdash}: The method of tissue acquisition was an important preanalytic factor that determined whether a sample would be successfully sequenced and whether a clinically actionable genomic alteration would be detected.},
	issn = {1543-2165},
	doi = {10.5858/arpa.2021-0313-OA},
	author = {Mata, Douglas A and Harries, Lukas and Williams, Erika and Hiemenz, Matthew C and Decker, Brennan and Tse, Julie Y and Janovitz, Tyler and Ferguson, Donna C and Speece, Iain A and Margolis, Matthew L and Mathews, Benjamin and Fedorchak, Kyle and Killian, J Keith and Xiao, Jinpeng and Tolba, Khaled A and Ramkissoon, Shakti and Vergilio, Jo-Anne and Elvin, Julia A and Oxnard, Geoffrey R and Ross, Jeffrey S and Huang, Richard S P}
}
